Financial review Satisfactory financial performance and a strong balance sheet The Group and its portfolio Companies Statement of comprehensive income A summary analysis of the Groups financial performance during saw a number of significant the year is provided below: developments during the year.
From 2014 2013 a financial perspective, the Group had m m another profitable year, although it Net portfolio gains 22.8 83.0 was less profitable than in 2013 and, Licensing income 3.0 following the acquisition of Fusion IP Other income 2.6 2.4 and equity fundraisings in the early Change in fair value of Oxford part of both 2014 and 2015, the Group Equity Rights asset 1.8 5.0 continues to benefit from a substantial Amortisation of intangible assets 4.9 balance sheet.
Acquisition costs 1.1 Greg Smith Chief Financial Officer Administrative expenses Modern Biosciences plc 1.8 0.5 Administrative expenses all other businesses 9.9 7.7 Finance income 0.6 0.4 Profit and total comprehensive income for the year 9.5 72.6 Net portfolio gains consist primarily of realised and unrealised fair value gains and losses from the Groups equity and debt holdings in spin-out businesses as well as changes in the fair value of its limited and limited liability partnership interests.
A detailed analysis of fair value gains and losses is provided in the Portfolio review on pages 18 to 29.
IP Group plc Annual Report and Accounts for the year ended 31 December 2014 30 23830.04 Proof 7 1-04-2015 Strategic Report Our Performance Strategic Report Our Performance Other income for the year remained relatively consistent Total equity net assets m at 2.6m 2013: 2.4m.
Other income comprises fund management fees, as well as consulting and similar fees typically 526.2m 2013: 336.6 m chargeable to its portfolio companies for services including executive search and selection, legal and administrative support.
526.2 Fund management fees are received from the Groups three managed funds, two of which also have the potential to generate performance fees from successful investment performance IP 336.6 Venture Fund IPVF and North East Technology Fund NETF.
263.1 221.6 As a result of an extension by its limited partner during the period, 173.1 NETFs investment period is now anticipated to continue until the end of 2015, while that of IPVF ceased in 2012.
The fund 2010 2011 2012 2013 2014 management fees for both funds reduce following the cessation of their investment periods.
The results of the Groups third managed fund, IPVFII, are consolidated into those of the Group Profit loss attributed to equity holders m and accordingly the fund management fees received are not reflected in the statement of comprehensive income.
9.5m 2013: 72.6m As a result of Modern Biosciences plcs R&D alliance and global 72.6 option and licence agreement with Janssen Biotech, Inc. Janssen, the Group became entitled to an upfront payment 40.7 of 3.0m 2.1m net of sub-licensing and other costs during the period, which was subsequently received in cash in January 2015.
The Group allocated an increased level of capital to the 9.5 1.8 5.5 evaluation and development of certain early-stage therapeutic 2010 2011 2012 2013 2014 programmes, including through its subsidiary Modern Bioscience plc MBS, during the year.
The majority of these costs related to the OxteoRx programme that is the subject of the R&D Cash, cash equivalents and deposits m alliance with Janssen.
All development costs are expensed to the statement of comprehensive income as they are incurred.
97.3m 2013: 24.1m MBS continued to benefit from the recovery of a proportion of the OsteoRx costs through a Biomedical Catalyst grant, with the 97.3 net expense being reflected in the statement of comprehensive 60.5 income.
The Group intends to continue developing a small number of early-stage therapeutic assets.
47.9 The Groups administrative expenses, excluding those relating to 24.1 MBS, increased during the period to 9.9m 2013: 7.7m.
This is 21.5 predominantly due to an increase in the cost base, following the 2010 2011 2012 2013 2014 Fusion IP plc Fusion IP acquisition, and is inclusive of an IFRS 2 share-based payments charge totalling 0.9m 2013: 0.9m, which relates to the Groups Long-Term Incentive Plan and Annual Incentive Scheme awards.
This non-cash charge reflects the fair value of services received from employees, measured by reference to the fair value of the share-based payments at the date of award, but has no net impact on the Groups total equity or net assets.
As a result of the Groups 97.4m equity capital raising net of expenses at the beginning of the year, and the resultant increased average cash balance during the year, the Groups interest receivable during the period increased to 0.6m 2013: 0.4m.
com 31 23830.04 Proof 7 1-04-2015 Financial review continued The Groups statement of financial position includes goodwill Statement of financial position of 57.1m 2013: 18.4m, acquired intangible assets of 16.5m The Group ended the period with net assets attributable to and an equity rights asset of 1.1m 2013: 2.9m.
The goodwill shareholders of 526.2m, representing an increase of 189.2m and acquired intangible assets values arose as a result of the from the position at 1 January 2014 337.0m.
As described Groups acquisition of Fusion IP.
The previous years goodwill above, the most significant contributing factors to the increase balance arose from historical acquisitions of Techtran Group in net assets during the period was the 97.4m net of expenses Limited university partnership business, 16.3m: 2013: 16.3m capital raising, the acquisition of Fusion IP and the performance and Top Technology Ventures Limited venture capital fund of the Groups portfolio of holdings in spin-out companies.
The intangible net assets, i. e. those excluding intangible assets and the Oxford assets are separately identifiable assets resulting from Fusion Equity Rights asset, totalled 451.3m at 31 December 2014 2013: IPs agreements with its partner universities.
intangible assets will be amortised on a straight line basis over At 31 December 2014 the Group held cash and deposits of each partnerships useful economic life.
97.3m 2013: 24.1m and a diversified portfolio of equity and The equity rights asset represents amounts paid to the University debt investments in 90 private and publicly listed technology of Oxford in 2000 and 2001 giving the Group the right to receive companies 2013: 72, 13 of which were added to the Groups 50% of the universitys entitlement to equity in any spin-out portfolio as a result of the Fusion IP acquisition.
company and of any licensing income emanating from the The value of the Groups holdings in portfolio companies University of Oxfords Department of Chemistry until November increased to 349.9m at year end 2013: 285.9m after net 2015.
Based on the Directors calculations, and as described unrealised fair value gains of 20.7m and net investment of more fully in note 14 to the Groups financial statements, the 37.1m 2013: 82.4m net unrealised fair value gain: 22.0m net fair value of the contract at 31 December 2014 has reduced by investment.
The Portfolio review on pages 18 to 29 contains a 1.8m 2013: 5.0m to 1.3m 2013: 3.1m and its value by 31 detailed description of the Groups portfolio of equity and debt December 2015 will be nil.
investments including key developments and movements during Due to the nature of its activities, the Group has limited current the year.
assets or current liabilities other than its cash and short-term deposit balances, which are considered in more detail opposite.
IP Group plc Annual Report and Accounts for the year ended 31 December 2014 32 23830.04 Proof 7 1-04-2015 Strategic Report Our Performance Strategic Report Our Performance It remains the Groups policy to place cash, which is surplus Cash, cash equivalents and short-term to near-term working capital requirements, on short-term and deposits Cash overnight deposits with financial institutions that meet the The principal constituents of the movement in Cash during the Groups treasury policy criteria or in low-risk treasury funds rated year are summarised as follows: A or above.
The Groups treasury policy is described in detail in 2014 2013 note 2 to the Group financial statements alongside details of the m m credit ratings of the Groups cash and deposit counterparties.
Net cash used in operating At 31 December 2014, the Group recognised 4.5m of loans activities excluding cash flows 2013: 1.3m from the limited partners of IPVFII, a fund raised to from deposits 6.4 1.9 during 2013 that is consolidated by the Group.
These loans are Net cash used in investing repayable only upon IPVFII generating sufficient returns to repay activities 35.4 21.9 the limited partners.
Whilst the Group continued to have no Issued share capital 97.4 borrowings, it may in the future consider introducing a modest level of gearing into the business if this is considered to be in the Acquisition of subsidiary 17.6 best interests of the Group.
Movement during period 73.2 23.8 At 31 December 2014 the Group had a total of 1.2m 2013: 0.1m in US Dollars held to meet the short-term At 31 December 2014, the Groups Cash totalled 97.3m, an working capital requirements of its US operations, including increase of 73.2m from a total of 24.1m at 31 December 2013 capital anticipated to be required by new and existing spin-out predominantly due to a net 97.4m increase from the issue of company opportunities.
new equity capital and 17.6m through the acquisition of Fusion IP offset by net investment in the Groups spin-out companies.
Taxation The Groups net cash used in investing activities increased during Since the Groups activities, including its activities in the US, 2014, reflecting both an increase in investments 2014: 46.8m: are substantially trading in nature the Directors continue to 2013: 27.5m and an increase in realisations 2014: 9.7m: 2013: believe that the Group qualifies for the Substantial Shareholdings 5.5m.
As described in more detail in the Portfolio review on Exemption SSE on chargeable gains arising on the disposal of pages [14] to [26], the Group allocated a total of 46.8m across qualifying holdings and, as such, the Group has continued not to 51 portfolio companies during the period 2013: 27.5m: 44 recognise a provision for deferred taxation in respect of uplifts in companies.
value on those equity stakes which meet the qualifying criteria.
The Groups unrecognised deferred tax assets and liabilities are A further 0.3m was committed to IP Venture Fund 2013: set out in note 9 to the financial statements.
0.2m, which in turn invested 2.7m across eight portfolio companies 2013: 1.4m: 6 companies.
The Group received a distribution of 1.1m following IP Venture Fund realising 11.1m from two exits and one partial disposal.
Overall, net cash used in investing activities totalled 35.4m 2013: 21.9m.
Primarily as a result of an increase in the Groups cost base post the acquisition of Fusion IP, cash used in operating activities increased to 6.4m 2013: 1.9m.
